Company profile · Public records

Saptalis Pharmaceuticals

Free public records show Saptalis Pharmaceuticals in 1 of the markets we cover. It is not a key player in our research.

0Reports naming them
1Markets in public records
0Regions & countries
See reportsGrowth in full reports

Public data

Free public data on Saptalis Pharmaceuticals

From public registers, not from Acuitas research, with a citation under every number. Each card opens the full list at its source.

About our sources

US drug approvals

6 approvals with a product on the US market

Tofacitinib Citrate ANDA218900 · approved 9 Jun 2026
Cyclosporine ANDA211943 · approved 5 Jul 2024
Likmez NDA216755 · approved 22 Sep 2023
Metformin Hydrochloride ANDA211309 · approved 3 Mar 2020
Clobetasol Propionate ANDA211494 · approved 2 Oct 2019

Source: Drugs@FDA, Approvals (NDA, ANDA, BLA) held, with a product sold now; newest shown. Retrieved 13 Nov 2026.

See them on openFDA

Markets where public records show them

Markets we cover where free public records show Saptalis Pharmaceuticals: trials they lead, US approvals or WHO prequalification. Each opens the market's report, with the record counts and their sources.

JAK Inhibitors

Topics

The topics of the markets Saptalis Pharmaceuticals is in.

All topics

Autoimmune diseases

Search all reports for Saptalis Pharmaceuticals All companies